Menu
News
Recent news
Santersus AG today announced the successful completion of its Series A financing, led by Norcliffe, a UK life sciences fund with participation from Terumo Ventures. The financing will support the advancement of Santersus’ NucleoCapture™ into pivotal clinical development while accelerating progress across Santersus’ broader pipeline.
December 11, 2025
Santersus AG today announced two senior leadership appointments that strengthen the company’s executive and governance capabilities as it advances its NucleoCapture™ toward pivotal clinical development.
August 27, 2025
Santersus AG today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its NucleoCapture™ blood purification technology for the treatment of severe, treatment-refractory systemic lupus erythematosus (SLE). This marks the second Breakthrough Device Designation awarded to NucleoCapture™, following earlier recognition for the treatment of sepsis.
Santersus AG congratulates its alliance partner OrganOx Ltd on the company’s acquisition by Terumo Corporation in a transaction valued at up to $1.5 billion — a major milestone in the evolution of global transplant technologies.
January 11, 2021
First patients is enrolled to First In-Human Clinical Trial of NucleoCapture®
December 2, 2021
Ethics Committees of two major clinics approved NucleoCapture to proceed with a clinical trial in Sepsic Patients
November 26, 2021
Santersus’ Shareholders Elect New Board Members
September 22, 2021
Santersus AG Confirms Attendance at BioTech Gate
September 1, 2021
Santersus Raises CHF 750 thousand in Family & Friends Round
1 2 3 >
All news
Ageing and rejuvenation
January 20, 2022
Santersus completes first clinical trial for sepsis and Covid-19 treatment
September 30, 2021
Santersus’ therapeutic technology helps to treat sepsis
March 17, 2021